US FDA has granted Orphan Drug Designation to Certa Therapeutics’ lead candidate FT011 for treatment of Systemic Sclerosis
Exciting news for portfolio company Certa Therapeutics. The US FDA has just granted Orphan Drug Designation to their lead candidate FT011, developed for the treatment of Systemic Sclerosis (SSc). SSc is an autoimmune disease causing inflammation and fibrosis of the skin and other organs.
This designation not only fast-tracks the path to market but also underscores the urgent need for a treatment option for this debilitating disease.
Congratulations team on achieving this key milestone!
To read more on this announcement, head to https://lnkd.in/gWpUnW2P